Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
Maria Moscvin(Brigham and Women's Hospital), Giada Bianchi(Brigham and Women's Hospital), Efstathios Kastritis(National and Kapodistrian University of Athens), Christine‐Ivy Liacos(National and Kapodistrian University of Athens), Peter G. Czarnecki(Beth Israel Deaconess Medical Center), Meletios Α. Dimopoulos(Korea University), Shahrier Hossain(National and Kapodistrian University of Athens), Paul G. Richardson(Harvard University), Niccolò Bolli(University of Milan), Foteini Theodorakakou(National and Kapodistrian University of Athens), Filippo Bagnoli(University of Milan), Houry Leblebjian(Dana-Farber Cancer Institute), Despina Fotiou(National and Kapodistrian University of Athens), Tianzeng Chen(Brigham and Women's Hospital), Helmut G. Rennke(Brigham and Women's Hospital), Eileen Regan(Dana-Farber Cancer Institute), Sean Rowell(Dana-Farber Cancer Institute)
Cited by 20
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k